Ardelyx, Inc. (ARDX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.27: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 10.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 15.75; Below-average business quality; Negative price momentum.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with... Read more
Sell if holding. Engine safety override at $6.27: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 10.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 15.75; Below-average business quality; Negative price momentum. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 6.1/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 75d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Ardelyx, Inc.
Latest news
- Ardelyx Presents Data Analysis Evaluating Long-Term Impact Of XPHOZAH On Serum Electrolytes And Selected Nutrition Bioma — benzinga May 7, 2026 positive
- Ardelyx Q1 EPS $(0.15) Misses $(0.13) Estimate, Sales $94.473M Beat $92.655M Estimate — benzinga Apr 30, 2026 positive
- Earnings Scheduled For April 30, 2026 — benzinga Apr 30, 2026 neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.27: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 10.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 15.75; Below-average business quality; Negative price momentum. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $5.86. Score 6.1/10, moderate confidence.
Take-profit target: $14.21 (+125.4% upside). Prior stop was $5.86. Stop-loss: $5.86.
Quality below floor (3.9 < 4.0).
Ardelyx, Inc. trades at a P/E of N/A (forward 11.8). TrendMatrix value score: 8.8/10. Verdict: Sell.
17 analysts cover ARDX with a consensus score of 4.5/5. Average price target: $16.
What does Ardelyx, Inc. do?Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and...
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.